Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$1.5 million.

  • Enanta Pharmaceuticals' Change in Receivables rose 516.34% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $236000.0, marking a year-over-year increase of 11199.19%. This contributed to the annual value of $236000.0 for FY2025, which is 11199.19% up from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Change in Receivables is -$1.5 million, which was up 516.34% from $1.5 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Change in Receivables high stood at $4.1 million for Q4 2021, and its period low was -$11.6 million during Q1 2021.
  • For the 5-year period, Enanta Pharmaceuticals' Change in Receivables averaged around -$1.3 million, with its median value being $420000.0 (2024).
  • In the last 5 years, Enanta Pharmaceuticals' Change in Receivables tumbled by 132502.98% in 2023 and then soared by 34308.39% in 2024.
  • Enanta Pharmaceuticals' Change in Receivables (Quarter) stood at $4.1 million in 2021, then plummeted by 44.33% to $2.3 million in 2022, then tumbled by 119.45% to -$441000.0 in 2023, then soared by 343.08% to $1.1 million in 2024, then tumbled by 235.35% to -$1.5 million in 2025.
  • Its Change in Receivables stands at -$1.5 million for Q3 2025, versus $1.5 million for Q2 2025 and -$926000.0 for Q1 2025.